Impact of recombinant factor VIII on hemophilia care.
Mannucci
P M
PM
Institute of Internal Medicine, University of Milan, Italy.
D000328:Adult; D000818:Animals; D016466:CHO Cells; D002986:Clinical Trials as Topic; D006224:Cricetinae; D005169:Factor VIII / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use*; D006467:Hemophilia A / Q000628:therapy*; D006801:Humans; D007518:Isoantibodies / Q000276:immunology; D011993:Recombinant Fusion Proteins / Q000276:immunology / Q000627:therapeutic use*; D012449:Safety; D012709:Serum Albumin; D014841:von Willebrand Factor / Q000235:genetics
D007518:Isoantibodies; D011993:Recombinant Fusion Proteins; D012709:Serum Albumin; D014841:von Willebrand Factor; D005169:Factor VIII